In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Sangamo Therapeutics Inc (NASDAQ: SGMO) was $0.50 for the day, down -3.08% from the previous closing price of $0.52. In other words, the price has decreased by -$3.08 from its previous closing price. On the day, 5.17 million shares were traded.
Ratios:
Our analysis of SGMO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.76. In the meantime, Its Debt-to-Equity ratio is 5.07 whereas as Long-Term Debt/Eq ratio is at 5.07.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.94 while its Price-to-Book (P/B) ratio in mrq is 23.11.
Stock Price History:
Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.30. The 50-Day Moving Average of the stock is -17.95%, while the 200-Day Moving Average is calculated to be -56.78%.
Shares Statistics:
A total of 245.40M shares are outstanding, with a floating share count of 237.58M. Insiders hold about 3.19% of the company’s shares, while institutions hold 21.61% stake in the company.
Earnings Estimates
Investors are keenly observing as 3.0 analysts analyze and rate the current performance of Sangamo Therapeutics Inc (SGMO) in the stock market.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.1 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.39 and -$0.54 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is -$0.4, with 3.0 analysts recommending between -$0.35 and -$0.46.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $100M to a low estimate of $400k. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $356k
A total of 6 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $106.4M, while the lowest revenue estimate was $20.8M, resulting in an average revenue estimate of $53.4M. In the same quarter a year ago, actual revenue was $57.8MBased on 6 analysts’ estimates, the company’s revenue will be $45.52M in the next fiscal year. The high estimate is $114.2M and the low estimate is $9.9M.
